ADMA Biologics Inc (ADMA)
NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ADMA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.92B
- P/E (TTM)
- 17.10
- Forward P/E
- 14.06
- EPS (TTM)
- $0.77
- Dividend yield
- None
- 52-week range
- 7.21 – 20.46
- Day range
- 13.13 – 13.47
- Volume / Avg
- 2.45M / 3.23M
- Beta
- —
- Shares outstanding
- 221.85M
52-week range
ADMA stock today
On Nov 20, ADMA ended the session at $13.17, shedding $0.17 (1.27%), versus the S&P 500's 3.70% decline. Shares are 35.6% below their 52-week high of $20.46, set on Dec 12, 2025 and 82.7% above the 52-week low of $7.21, in the middle of the past year's range. ADMA is down 27.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 23.3%.
ADMA Biologics trades at 17.1x its trailing twelve-month earnings per share of $0.77. Its forward P/E of 14.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About ADMA Biologics
Company profileADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Adam S. Grossman
- Headquarters
- Ramsey, NJ
- Employees
- 640
- Website
- admabiologics.com
Financial highlights
Full financialsIn fiscal 2025, ADMA Biologics generated $510.2 million in revenue, up 19.6% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $146.9 million (-25.7% year over year), for a net margin of 28.8% versus a median of -42.8% in the prior 5 years. Gross margin was 57.4% (up from 51.5%) and operating margin 37.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $510.17M | $426.45M | $258.21M | $154.08M | $80.94M |
| Growth | +19.63% | +65.15% | +67.59% | +90.36% | +91.72% |
| Net income | $146.93M | $197.67M | $-28.24M | $-65.90M | $-71.65M |
| EPS (diluted) | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 |
Analyst forecast
ForecastConsensus (4 analysts)
buy
Avg. price target
$18.00+36.67%
- Strong buy 1
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.22 vs $0.19
- Surprise
- +15.79%
ADMA news
All ADMA news- ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?NasdaqADMA, GRFS, TAK
- ADMA Biologics (ADMA) Q3 2026 Earnings Call TranscriptNasdaqADMA, ET
- ADMA Biologics hits 10-month high as Asceniv drives Q3 beatSeeking Alpha
- ADMA Biologics Q3 Profit Jumps 37%; Reiterates FY26 Revenue Outlook, Stock Up 23%NasdaqADMA, BRK.A
- Adma Biologics reiterates at least $530M 2026 revenue and raises minimum adjusted EBITDA to at least $275M as ASCENIV demand acceleratesSeeking Alpha
- ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswire
- ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing ProcessGlobeNewswire
ADMA Biologics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DNLIDenali Therapeutics Inc. | 18.45 | +1.37% | $2.96B | vs ADMA |
| VCELVericel Corporation | 57.52 | -1.27% | $2.94B | vs ADMA |
| IOVAIovance Biotherapeutics Inc. | 6.90 | -5.61% | $3.19B | vs ADMA |
| RLAYRelay Therapeutics Inc. | 16.12 | +1.32% | $3.56B | vs ADMA |
| TARSTarsus Pharmaceuticals Inc. | 73.01 | -6.00% | $3.60B | vs ADMA |
| BEAMBeam Therapeutics Inc. | 20.90 | -0.19% | $2.16B | vs ADMA |
| CRSPCRISPR Therapeutics AG | 39.10 | +0.44% | $3.79B | vs ADMA |
| BCRXBioCryst Pharmaceuticals Inc. | 7.22 | -1.37% | $1.86B | vs ADMA |
Indexes, lists and sector
ADMA Biologics stock FAQ
What is ADMA Biologics's stock price today?
ADMA last traded at $13.17 as of Nov 20, 4:00 PM EST, down 1.27% on the day. Prices are delayed at least 15 minutes.
What is ADMA's P/E ratio?
ADMA trades at a trailing P/E ratio of 17.10 and a forward P/E of 14.06.
Who is ADMA Biologics's CEO?
Mr. Adam S. Grossman is the chief executive officer of ADMA Biologics Inc, which has about 640 employees.
What is the ADMA 52-week high?
The 52-week high for ADMA is $20.46 and the 52-week low is $7.21. The stock is currently 35.6% below its high.